Overview of the drug development pipeline for neutropenia
Neutropenia occurs owing to the low count of white blood cells in the body, termed as neutrophils. Leukemia is the most common type of cancer occurring in adults and children. Individuals with neutropenia are susceptible to contracting serious infections, that result in occurring of various cancers in the body. Patients experience symptoms such as ulcers, abscesses, rashes, pneumonia, and fever. Medical practitioners have identified that neutropenia occurs due to decreased bone marrow production and increased destruction of neutrophils in the peripheral blood. With the increasing instances of neutropenia in children and adults, Technavio's market research analysts have reported increasing drug development for therapeutics to treat neutropenia in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical and phase II drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the phase I and discovery drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase II/III and phase III stage.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of neutropenia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- PROLONG PHARMACEUTICALS
- SPECTRUM PHARMACEUTICALS
- SYROS PHARMACEUTICALS
Therapeutic assessment of the drug development pipeline for neutropenia by route of administration
- Subcutaneous
- Oral
- Intravenous
In the subcutaneous route of administration (ROA), the drug substances are administered directly into the layer of the skin below the dermis and the epidermis. It has been observed that the majority of total therapeutics for neutropenia are being developed for subcutaneous administration.
Therapeutic assessment of the drug development pipeline for neutropenia by therapies employed
- Monotherapy
- Combination therapy
According to this pipeline analysis report, molecules are developed in the monotherapy method of therapeutics. In this therapy employed, a single drug is administered to treat a particular disorder.
Technavio also offers customization on reports based on specific client requirement.